Cempra (CEMP) : The consensus on Cempra (CEMP) based on 11 analyst recommendation on the company stock is 1.41, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 8 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Cempra (CEMP) : The highest short term price target forecast on Cempra (CEMP) is $51 and the lowest target price is $20. A total of 10 equity analysts are currently covering the company. The average price of all the analysts is $37.3 with a standard deviation of $9.79.
For the current week, the company shares have a recommendation consensus of Buy.
Cempra (NASDAQ:CEMP): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $18.89 and $18.18 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $19.40. The buying momentum continued till the end and the stock did not give up its gains. It closed at $18.88, notching a gain of 4.54% for the day. The total traded volume was 1,122,750 . The stock had closed at $18.06 on the previous day.
Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.